Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Gut microbiota dysbiosis promotes neuroinflammation in Alzheimer's disease progression

Nov. 21, 2019

IND approval and patent application for the first-ever liquid formulation of topiramate

Nov. 21, 2019

Scholar Rock reports preliminary PK and PD data from phase II study of SRK-015 in SMA

Nov. 20, 2019

Haplodeficiency disrupts microglial responses in AD models

Nov. 20, 2019

Integrated stress response backfires in Down syndrome

Nov. 20, 2019

BioArctic to end SC-0806 development in complete spinal cord injury based on interim phase I/II data

Nov. 19, 2019

Merck & Co. divulges nicotinic acetylcholine alpha7 receptor PAMs

Nov. 19, 2019

Phase II study of KarXT for acute psychosis in schizophrenia meets primary endpoint

Nov. 19, 2019

Lineage Cell Therapeutics provides update on phase I/IIa SCiStar study of OPC-1

Nov. 19, 2019

New SCD1 and SCD5 inhibitors presented by Yumanity Therapeutics

Nov. 18, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...